Influence of malignancy on the pharmacokinetics of vancomycin hydrochloride in Japanese MRSA patients after dosage adjustment with the Bayesian method

Japanese Journal of Chemotherapy

Volumn 53, Issue 6, 2005, Pages 357-363

  Teramachi, Hitomi ^a   Matsushita, Ryo ^b   Tsuji, Akira ^b  

^a Department of Pharmacy   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Bayesian method; Malignancy; Pharmacokinetic parameter; Vancomycin

Indexed keywords

VANCOMYCIN;

ACCURACY; ADULT; AGED; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; FEMALE; HUMAN; JAPAN; KIDNEY FUNCTION; LUNG CANCER; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 22444446336     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Chinese source. 25: 517-524, 1999
2. Chinese source. 48: 545-552, 2000
3. Winter M E: Vancomycin. [i#In#1i] Basic Clinical Pharmacokinetics, p. 474-499, Applied Therapeutics, Vancouver, WA, 1994
4. Cantu T G, Yamanaka-Yuen N A, Lietman P S: Serum vancomycin concentrations: Reappraisal of their clinical value. Clinical Infections Diseases 18: 533-543, 1994
5. Chinese source. 17: 241-247, 2001
6. Kelman A W, Whiting B, Bryson S M: OPT: A package of computer programs for parameter optimisation in clinical pharmacokinetics. Br J Clin Pharmacl 14: 247-256, 1982
7. Chinese source. 14: 179-188, 1997
8. Yasuhara M, Iga T, Zenda H, et al: Population pharmacokinetics of vancomycin in japanese adult patients. Ther Drug Monit 20: 139-148, 1998
9. Cockcroft D W, Gault M H: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976
10. Sheiner L B, Beal S L: Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9: 503-512, 1981
11. Fernandez G M M, Fruns I, Hernandez J M, et al: Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies. Clin Pharm 12: 515-520, 1993
12. Chang D, Liem L, Malogolowkin M: A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients. Prediatr Infect Dis J 13: 969-974, 1994
13. Chang D: Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Prediatr Infect Dis J 14: 667-673, 1995
14. Krivoy N, Peleg S, Postovsky S, et al: Pharmacokinetic analysis of vancomycin in stedy state in pediatric cancer patients. Pediatr Hemat and Oncol 15: 333-338, 1998
15. Normand Y L, Milpied N, Kergueris M F, et al: Pharmacokinetic parameters of vancomycin for therapeutic regimens in neutropenic adult patients. Int J of Bio-Medical Comput 36: 121-125, 1994
16. Sun H, Maderazo E U, Krusell A R: Serum protein binding characteristics of vancomycin. Antimicrob Agents Chemother 37: 1132-1136, 1993
17. Chinese source. 9: 1465-1472, 1993
18. Aldaz A, Ortega A, Idoati A, et al: Effect of hepatic function on vancomycin pharmacokinetics in patients with cancer. Ther Drug Monit 22: 250-257, 2000